ライフサイエンスコーパス: fasting glucose

1 pite weight gain, KCl prevented worsening of fasting glucose.

2 tension, dyslipidemia, diabetes, or impaired fasting glucose.

3 olesterol, high blood pressure, and elevated fasting glucose.

4 ubstantial weight loss and reduced HbA1c and fasting glucose.

5 n cholesterol, central obesity, and elevated fasting glucose.

6 three primary outcomes were weaker than for fasting glucose.

7 diabetes and 266 participants with impaired fasting glucose.

8 g T2DM in individuals with isolated impaired fasting glucose.

9 tions for individuals with isolated impaired fasting glucose.

10 was no effect of nut consumption on HbA1c or fasting glucose.

11 seen for lipids, overall type 2 diabetes, or fasting glucose.

12 SLAMF1, APOBEC3H and the 15q26.1 region with fasting glucose.

13 tened insulin levels with trends of elevated fasting glucose.

14 s2282679 with any other traits and diseases: fasting glucose (0.00 mmol/l [95% CI -0.01, 0.01]; p = 1

15 olesterol showed associations with increased fasting glucose (0.09 mmol/L, 95% CI 0.02 to 0.15), body

16 1 kg/m(2) genetically elevated BMI increased fasting glucose (0.18 mmol/l; 95% confidence interval (C

17 s in leptin (-0.7 ng/mL; -2.1, 0.8 ng/mL) or fasting glucose (0.2 mmol/L; -0.5, 0.9 mmol/L) in men ex

18 ydrate with SFA had no significant effect on fasting glucose (+0.02 mmol/L, 95% CI = -0.01, +0.04; n

19 g/mL) higher leptin and tended to have lower fasting glucose (-0.8 mmol/L; -1.8, 0.2 mmol/L, nonsigni

20 Maternal GDM, fasting glucose, 1-h, and 2-h glucose concentrations fol

21 se or fasting glucose>/=126 mg/dL and IFG as fasting glucose 100-125 mg/dL.

22 There were no changes in weight, fasting glucose, 2-h glucose and insulin, haemoglobin A1

23 es), and glycaemic traits (concentrations of fasting glucose, 2-h glucose, fasting insulin, and HbA1c

24 /- 3.7; body fat percentage: 40.5% +/- 7.9%; fasting glucose: 6.3 +/- 0.6 mmol/L].

25 Changes in fasting glucose, acute insulin secretion (AIR), and insu

26 s not significantly associated with abnormal fasting glucose after considering the influence of OSA.

27 ) had impaired glucose tolerance or impaired fasting glucose and 171 entered the trial.

28 identified three transcripts associated with fasting glucose and 433 transcripts associated with fast

29 ng/mL), lack of outdoor exercise, increased fasting glucose and a family history of PCOS in at least

30 orted diabetes or diagnostic levels for both fasting glucose and calibrated HbA1c).

31 dence supporting causal associations between fasting glucose and cancer.

32 sed red meat was associated with both higher fasting glucose and fasting insulin concentrations after

33 F, we detected an interaction effect between fasting glucose and fasting triglycerides with rs9939609

34 Changes in fasting glucose and glycated haemoglobin were not differ

35 Laboratory status was improved, for example, fasting glucose and glycated hemoglobin decreased from 6

36 cid (UA) and diabetes-related traits such as fasting glucose and glycated hemoglobin.

37 th the M-value and inversely associated with fasting glucose and HbA(1c) (P < 0.05), whereas BRS was

38 ] with SCT) with 9062 concurrent measures of fasting glucose and HbA1c levels.

39 in the Si and AIR, along with an increase in fasting glucose and HbA1c.

40 and donor pairs showed significantly higher fasting glucose and hypertension in nondonors.

41 Fasting glucose and insulin are intermediate traits for

42 even on the chow diet; HFD further increased fasting glucose and insulin but not glucose intolerance.

43 and the interaction of meat with genotype on fasting glucose and insulin concentrations in Caucasians

44 The association of higher fasting glucose and insulin concentrations with meat con

45 to fasting glucose or insulin resistance on fasting glucose and insulin concentrations.

46 ed meat and unprocessed red meat intake with fasting glucose and insulin concentrations; and 2) the i

47 n urban areas, is negatively associated with fasting glucose and insulin levels, but most aspects of

48 ose of LES consumed, cointervention type, or fasting glucose and insulin levels.

49 ls, body mass index, height, blood pressure, fasting glucose and insulin, RR interval, fibrinogen lev

50 We have identified multiple QTLs for fasting glucose and lipid levels.

51 Fasting glucose and lipid metabolism, and body weight of

52 es, blood pressure, glycated hemoglobin, and fasting glucose and report the prevalence of abnormal va

53 Baseline fasting glucose and rs9939609 interacted on weight chang

54 Both HFD and Pb increased fasting glucose and serum leptin levels.

55 in concentrations of serum hsCRP and plasma fasting glucose and the proportion of arachidonic acid (

56 A significant correlation between fasting glucose and triglyceride levels was also observe

57 y, we investigated the interaction effect of fasting glucose and triglyceride levels with rs9939609 i

58 O) criteria to define GDM: >/=7.0 mmol/L for fasting glucose and/or >/=7.8 mmol/L for 2-h post-glucos

59 tension and smoking, higher body mass index, fasting glucose, and 10-year risk for CVD.

60 such as blood pressure, cholesterol levels, fasting glucose, and body mass index.

61 enome-wide significant associations for T2D, fasting glucose, and fasting insulin, comprising 65, 43,

62 the fatty acid composition of plasma lipids, fasting glucose, and high-sensitivity C-reactive protein

63 investigated between genotype, plasma PUFAs, fasting glucose, and hsCRP concentrations in the cross-s

64 six regions), measures of glycaemia (HbA1c, fasting glucose, and insulin concentrations, and Homeost

65 Weight, BMI, glycated hemoglobin A1c, fasting glucose, and insulin were abstracted by 2 indepe

66 ospective cohort, concentrations of 11 PFAS, fasting glucose, and lipids were measured in maternal mi

67 tatistically significant, for triglycerides, fasting glucose, and non-HDL cholesterol.

68 ressure, waist circumference, triglycerides, fasting glucose, and non-high-density lipoprotein (non-H

69 neonates but only persisted in girls between fasting glucose, and sSAT and dSAT at 4.5 y.

70 Processed meat was associated with higher fasting glucose, and unprocessed red meat was associated

71 worse triglycerides-, HDL-, blood pressure-, fasting glucose- and hemoglobin A1C values.

72 al, HDL, and LDL cholesterol; triglycerides; fasting glucose; AST; and ALT levels were analyzed on a

73 were positively associated with (changes in) fasting glucose at 24 and 32 wk.

74 (57.8%) of IFG donors had reverted to normal fasting glucose at a mean follow-up of 10.4 years.

75 ere aged 42-60 y and free of T2D or impaired fasting glucose at baseline in 1984-1989.

76 Lower FG fasting glucose at BR was more commonly associated with

77 Fasting glucose at re-assessment was also predictive of

78 elated variables (hemoglobin A1c [HbA1c] and fasting glucose) at baseline and with 6-month change in

79 n of patients achieving HbA1c below 6.5% and fasting glucose below 126 mg/dL was higher following RYG

80 e supplementation correlated with changes in fasting glucose (beta = 0.07; 95% CI: 0.01, 0.14; P = 0.

81 Allele C at rs3093059 was associated with fasting glucose (beta = 0.20, P = 0.045) and G at rs1205

82 The primary outcome was the change in fasting glucose between groups from preintervention to p

83 d race and factors including biological (eg, fasting glucose, body mass index), neighborhood (racial

84 otein- and total cholesterol, triglycerides, fasting glucose, body mass index, waist circumference, h

85 the proportion of participants with impaired fasting glucose but not a clinical diagnosis of diabetes

86 rol seem to be protective against increasing fasting glucose but not against type 2 diabetes.

87 n analyzing the combination effect of BP and fasting glucose, cancer risks were serially increased wi

88 lucose tolerance test (OGTT), although a non-fasting, glucose challenge test (GCT) is used in some pa

89 tic variants with inverse-normal transformed fasting glucose change over time adjusting for age at ba

90 t these data suggest that genetic effects on fasting glucose change over time are likely to be small.

91 Fasting glucose change over time was defined as the slop

92 1c were nominally (P < 0.05) associated with fasting glucose change over time.

93 ignificant association (P < 5 x 10(-8)) with fasting glucose change over time.

94 enome-wide association study of longitudinal fasting glucose changes in up to 13,807 non-diabetic ind

95 The C-statistics were 0.662 for ADA fasting glucose clinical concentration categories and 0.

96 and triglycerides and 0.2 mmol/l higher non-fasting glucose, compared with mothers of AGA offspring.

97 130 non-Western immigrants with prediabetes (fasting glucose concentration >5.5 mmol/L or random gluc

98 We compared prediabetes definitions based on fasting glucose concentration (American Diabetes Associa

99 ation and HbA1c were measured at visit 2 and fasting glucose concentration and 2 h glucose concentrat

100 -mmol/L (95% CI: 0.023, 0.051-mmol/L) higher fasting glucose concentration and a 0.049-ln-pmol/L (95%

101 Fasting glucose concentration and HbA1c were measured at

102 rofile, but resulted in reductions in BP and fasting glucose concentration and in improvements in ins

103 ent chronic kidney disease was 0.636 for ADA fasting glucose concentration clinical categories and 0.

104 erotic cardiovascular disease, 0.701 for ADA fasting glucose concentration clinical categories and 0.

105 ripheral arterial disease, and 0.683 for ADA fasting glucose concentration clinical categories and 0.

106 ucose concentration clinical categories, WHO fasting glucose concentration clinical categories, and A

107 ADA fasting glucose concentration clinical categories, WHO f

108 [9%] of 10 844 people; 8.4-9.5), and the WHO fasting glucose concentration cutoff (1213 [11%] of 10 8

109 Prediabetes defined using the ADA fasting glucose concentration cutoff (prevalence 4112 [3

110 tration (American Diabetes Association [ADA] fasting glucose concentration cutoff 5.6-6.9 mmol/L and

111 concentration cutoff 5.6-6.9 mmol/L and WHO fasting glucose concentration cutoff 6.1-6.9 mmol/L), Hb

112 The definition of prediabetes using the ADA fasting glucose concentration cutoff was more sensitive

113 ulin sensitivity increased at 3 and 6 mo and fasting glucose concentration declined at 6 mo (-2.67; 9

114 A fasting glucose concentration of 5.4 mmol/L or a 2 h pos

115 ion of 6.5% or less (</=47.5 mmol/mol) and a fasting glucose concentration of 5.6 mmol/L or less with

116 nsitivity (1/fasting insulin concentration), fasting glucose concentration, and lipid profile and to

117 were also associated with circulating higher fasting glucose concentration, bodyweight, and waist-to-

118 were also associated with circulating higher fasting glucose concentration, bodyweight, and waist-to-

119 s different prediabetes definitions based on fasting glucose concentration, HbA1c, and 2 h glucose co

120 al disease, and all-cause mortality than did fasting glucose concentration-based definitions (all p<0

121 h younger and older mothers had higher adult fasting glucose concentrations (roughly 0.05 mmol/L).

122 hance both glucagon and insulin secretion at fasting glucose concentrations and that FFAR1 and enhanc

123 D1/4KO mice displayed normal fasting glucose concentrations but had reduced tolerance

124 We have also shown that fat mass and fasting glucose concentrations were lower in TRPC1 KO mi

125 Fasting glucose concentrations were similar, whereas fas

126 mulates secretion of glucagon and insulin at fasting glucose concentrations.

127 model identified the combination of cT1-AST-fasting glucose (cTAG) as far superior to any individual

128 sterol, low-density lipoprotein cholesterol, fasting glucose, diabetes mellitus, glycohemoglobin, bod

129 h adjustment for BMI, the change in maternal fasting glucose did not differ significantly between tre

130 ociation between R3527Q variant and impaired fasting glucose, fasting glucose or insulin, or oral glu

131 rvention and control arms was determined for fasting glucose, fasting insulin, glycated hemoglobin (H

132 The changes in fasting glucose, fasting insulin, insulin resistance (ho

133 were assessed across subgroups defined upon fasting glucose (FG) and body mass index (BMI).

134 of two traits for diabetes diagnosis, serum fasting glucose (FG) and glycated hemoglobin (HbA(1c)),

135 Women without DM who had fasting glucose (FG) and insulin (FI) data for >=2 visit

136 2 diabetes (T2D)-related quantitative traits fasting glucose (FG) and insulin (FI) in African ancestr

137 ounded estimates of the influence of T2D and fasting glucose (FG) on CHD risk.

138 uding LDL cholesterol, triacylglycerol (TG), fasting glucose (FG), glycated hemoglobin (HbA1c), insul

139 CB0313.1 improved diabetic markers (fasting glucose, glucose tolerance, insulin tolerance, G

140 tent variable for glycemia (diabetes status, fasting glucose, glycated hemoglobin (HbA1c), fructosami

141 Cholesterols, fasting glucose, glycosylated haemoglobin, and proinflam

142 ore of five components present at diagnosis: fasting glucose > 100 mg/dL or diabetes; elevated blood

143 included female sex, body mass index >/=35, fasting glucose >5.5 mmol/L, and many ballooned cells, N

144 ients (55%) had either undiagnosed diabetes (fasting glucose >7.0 mmol/L, n=4) or insulin resistance

145 nesses) and HbA1c z-scores with dysglycemia (fasting glucose >=6.1 mmol/L with 2-hour glucose >=7.8 m

146 = 0.93, 95% CI = 0.88 to 0.97) with elevated fasting glucose (>/= 110 mg/dL) after adjustment for clu

147 no hypoglycemic medication use) or abnormal fasting glucose (>/=100 mg/dl and/or hypoglycemic medica

148 d diabetes was defined as elevated levels of fasting glucose (>/=7.0 mmol/L [>/=126 mg/dL]) and hemog

149 tes was defined by history/medication use or fasting glucose>/=126 mg/dL and IFG as fasting glucose 1

150 Laboratory data including serum fasting glucose, haemoglobin A1c levels, creatinine leve

151 In unadjusted GEE analyses, for a given fasting glucose, HbA1c values were statistically signifi

152 aortic pulse wave velocity, blood pressure, fasting glucose, HDL, LDL, or C-reactive protein.

153 with IR-related traits, including increased fasting glucose, hemoglobin A1C, total and LDL cholester

154 al metabolic rate, diastolic blood pressure, fasting glucose, high-density lipoprotein cholesterol, l

155 etes, hypertension, and CVD-risk biomarkers [fasting glucose, high-density lipoprotein, triglycerides

156 unspecified subtypes of MDD with changes of fasting glucose, high-density lipoprotein-cholesterol, t

157 fflux capacity after adjusting for age, sex, fasting glucose, homeostasis model assessment of insulin

158 alcohol use, hypertension, diabetes/impaired fasting glucose, homeostatic model assessment of insulin

159 I was associated with lower risk of elevated fasting glucose (HR: 0.80, 95% CI 0.70-0.92, P-trend = 0

160 was associated with development of impaired fasting glucose (IFG) after atenolol treatment.

161 t an oral glucose tolerance test as impaired fasting glucose (IFG) and high HbA(1c) are also used to

162 s assessing pre-hypertension and an impaired fasting glucose (IFG) and their combined effects on the

163 factors predictive of diabetes and impaired fasting glucose (IFG) in a large HBV-infected multiethni

164 their association with diabetes and impaired fasting glucose (IFG) in Fukuoka, Japanese subjects (n =

165 treatment of asymptomatic diabetes, impaired fasting glucose (IFG), or impaired glucose tolerance (IG

166 beta-cell function in subjects with impaired fasting glucose (IFG).

167 from 1994 to 2007 with predonation impaired fasting glucose (IFG).

168 10.7), 18% of the participants had impaired fasting glucose (IFG; i.e., 100-125 mg/dL FBG) at first

169 and no self-reported history of DM; impaired fasting glucose [IFG]: FPG 5.6-6.9 mmol/L and no self-re

170 of 4 screening tests in identifying impaired fasting glucose, impaired glucose tolerance (IGT), and N

171 iewed the evidence on screening for impaired fasting glucose, impaired glucose tolerance, and type 2

172 verweight or obese individuals with impaired fasting glucose, impaired glucose tolerance, or both [22

173 patients (n = 28) met criteria for impaired fasting glucose/impaired glucose tolerance or diabetes.

174 olerance: normal glucose tolerance, impaired fasting glucose/impaired glucose tolerance, or diabetes.

175 Salsalate treatment increased VO2, lowered fasting glucose, improved glucose tolerance, and led to

176 e serially increased with an increase in the fasting glucose in a dose-dependent manner, but not with

177 A was significantly associated with abnormal fasting glucose in African Americans (odds ratio, 2.14;

178 usly unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variatio

179 predictive of future GDM diagnoses than was fasting glucose in early pregnancy.

180 erence, and 1.6% (95% CI: - 0.6, 3.8) higher fasting glucose in fully adjusted models.

181 circulating metabolites that correlate with fasting glucose in the Erasmus Rucphen Family (ERF) stud

182 SLC5A1 showed a significant association with fasting glucose in the expected opposing direction.

183 the pathway between early-life nutrition and fasting glucose in women.

184 Glucose metabolism parameters including fasting glucose, insulin and homeostasis model of assess

185 associated with intermediate outcomes (e.g., fasting glucose, insulin resistance) during childhood.

186 The markers examined included fasting glucose, insulin, adiponectin, and glycated albu

187 asis model assessment of insulin resistance; fasting glucose, insulin, and lipids; body mass index (B

188 ths-6.5 years, and ages 6.5-11.5 years) with fasting glucose, insulin, insulin resistance, beta-cell

189 hs to 6.5 years, and 6.5 to 11.5 years) with fasting glucose, insulin, insulin resistance, beta-cell

190 ), but otherwise no changes were observed in fasting glucose, insulin, ketones, and renal function.

191 nergy expenditure, respiratory quotient, and fasting glucose, insulin, total and high-density lipopro

192 tion, routine biochemical parameters such as fasting glucose, insulin, total cholesterol, high-densit

193 .2%, -0.7%); HC diet: -1.0% (-1.3%, -0.8%)], fasting glucose [LC diet: -0.7 mmol/L (-1.3, -0.1 mmol/L

194 ted HMOs 3'SL and 3'SLN were associated with fasting glucose; LDFT was associated with fasting insuli

195 We defined diabetes as a fasting glucose level >/=126 mg/L (or >/=200 mg/L for th

196 ntly of this, with a steeper increase of the fasting glucose level (beta=131; 95% CI 38-225) during f

197 lucose and lipid metabolism, associated with fasting glucose level (P = 1.80 x 10(-8)).

198 PM2.5 exposure during trimester 2 increased fasting glucose level by 0.85% (95% CI: 0.41, 1.29).

199 creasing levels of alanine aminotransferase, fasting glucose level, hypertension (each P < .01), and

200 ipoprotein (HDL) cholesterol level, impaired fasting glucose level, type 2 diabetes mellitus, hyperte

201 efit for cardiometabolic outcomes, including fasting glucose level.

202 ody mass index, systolic blood pressure, and fasting glucose level.

203 tolic blood pressure, diabetes mellitus, and fasting glucose level.

204 rends in HbA1c categories were compared with fasting glucose levels (>/=7.0 mmol/L [>/=126 mg/dL] and

205 0%), elevated blood pressure (49%), impaired fasting glucose levels (26%), and diabetes mellitus (14%

206 = .01) but were less likely to have impaired fasting glucose levels (adjusted relative risk = 0.58 [9

207 r the remission of MetS identified that only fasting glucose levels (OR = 13.4; P = 0.01) and duratio

208 requently overweight (p = 0.046), had higher fasting glucose levels (p = 0.037), better scores at the

209 the minor allele of rs11932595 showed higher fasting glucose levels (p = 0.044) and better scores at

210 including survival, bodyweight, food intake, fasting glucose levels and age-related morbidity.

211 we show that hepatic GCN5L1 ablation reduces fasting glucose levels and blunts hepatic gluconeogenesi

212 Fasting glucose levels and carotid ultrasonography measu

213 Reductions in fasting glucose levels and hemoglobin A1c were greater a

214 production of GS-HNE associated with higher fasting glucose levels and moderately impaired glucose t

215 0.3 vs. 2.2 +/- 0.44 kg/m(2) in persons with fasting glucose levels below and above the median, respe

216 AG infusion raised fasting glucose levels but had no effect on fasting plas

217 calibrated HbA1c levels than when defined by fasting glucose levels but has increased from 5.8% in 19

218 iabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in

219 miR administration lowered random as well as fasting glucose levels in diabetic mice.

220 At 12 months, fasting glucose levels in the control group had increase

221 Higher fasting glucose levels may amplify obesity-risk in FTO c

222 Supporting NHANES analyses showed that fasting glucose levels of obese adults were inversely re

223 Variants associated with type 2 diabetes and fasting glucose levels reside in introns of ADCY5, a gen

224 low-density lipoprotein cholesterol levels, fasting glucose levels, and adiposity at 12 to 24 months

225 sitivity C-reactive protein levels, impaired fasting glucose levels, dyslipidemia, elevated blood pre

226 The risk of impaired fasting glucose levels, elevated blood pressure, and ele

227 found stress to be associated with increased fasting glucose levels, especially among those who resid

228 variants were significantly associated with fasting glucose levels, including a nonsynonymous coding

229 iculum (ER) stress related gene expressions, fasting glucose levels, insulin sensitivity and restored

230 ffective despite improving plasma lipids and fasting glucose levels.

231 ], and 3 suggestive QTLs were identified for fasting glucose levels.

232 otic medications can lose weight and improve fasting glucose levels.

233 , regardless of their cholesterol ratios and fasting glucose levels.

234 fication on high-fat diet without changes in fasting glucose, lipids, or body composition.

235 or more cardiometabolic abnormalities (high fasting glucose, low high-density lipoprotein cholestero

236 ined as having blood pressure <120/80 mm Hg, fasting glucose <100 mg/dl, glycosylated hemoglobin <5.7

237 and untreated blood pressure <140/90 mm Hg, fasting glucose <126 mg/dl, total cholesterol <240 mg/dl

238 Subjects were classified as having normal fasting glucose (<100 mg/dl and no hypoglycemic medicati

239 arter mile) was associated with increases in fasting glucose (mean = 0.22 mg/dL, 95% confidence inter

240 protein electrophoresis with immunofixation, fasting glucose measurement, and glucose tolerance test.

241 as the slope of the line defined by multiple fasting glucose measurements obtained over up to 14 year

242 letters, pharmacy dispensing data, and serum fasting glucose measurements taken at the study centre (

243 tors of insulin sensitivity, and measures of fasting glucose metabolism.

244 IR was computed as fasting insulin (mIU/L) x fasting glucose (mmol/L)/22.5.

245 Eight subjects with normal fasting glucose (NFG) and eight subjects with IFG receiv

246 ere defined on the basis of WHO criteria for fasting glucose (normoglycaemia: </=6.0 mmol/L; prediabe

247 onsidered type 2 diabetes (T2D, NSNPs = 49), fasting glucose (NSNPs = 36), insulin resistance (NSNPs

248 asting glucose, with a mean +/- SD change in fasting glucose of -1.1 +/- 8.4 mg/dL compared with an i

249 -C of 1.35 (CI, 1.26-1.45), and for impaired fasting glucose of 1.31 (CI, 1.05-1.64).

250 15 male subjects with HbA1c of 5.7 +/- 0.1%, fasting glucose of 114 +/- 3 mg/dL, and 2-h glucose of 1

251 Seven loci previously associated with T2D, fasting glucose or HbA1c were nominally (P < 0.05) assoc

252 re attenuated with additional adjustment for fasting glucose or HbA1c.

253 1), but no overall effects were observed for fasting glucose or HbA1c.

254 the inclusion criteria (NAFLD with impaired fasting glucose or impaired glucose tolerance) and were

255 have diabetes and another 37% have impaired fasting glucose or impaired glucose tolerance.

256 tolerance, and 21 participants had impaired fasting glucose or impaired glucose tolerance.

257 al glucose tolerance and those with impaired fasting glucose or impaired glucose tolerance.

258 ts did not differ by type or dose of LES, or fasting glucose or insulin levels.

259 red meat with genetic risk score related to fasting glucose or insulin resistance on fasting glucose

260 modified by genetic loci known to influence fasting glucose or insulin resistance.

261 R3527Q variant and impaired fasting glucose, fasting glucose or insulin, or oral glucose tolerance te

262 ssociated with the clinical glycemic markers fasting glucose or the HbA1c, and vice versa.

263 % confidence interval, 1.2-2.0) and elevated fasting glucose (OR, 1.6; 95% confidence interval, 1.1-2

264 se tolerance) and/or fasting state (impaired fasting glucose) or by intermediate HbA(1c) levels.

265 actors (hypertension, dyslipidemia, impaired fasting glucose, or the metabolic syndrome).

266 ive associations between telomere length and fasting glucose (P = 0.003) and HbA1c (P = 0.0008) were

267 PPP1R3B was associated with higher levels of fasting glucose (P = 7.70 x 10-7) and fasting insulin (P

268 ncentrations were positively correlated with fasting glucose, plasma leptin, and apolipoprotein C3 (A

269 tional diabetes mellitus (GDM) that included fasting glucose, prepregnancy BMI, gestational weight ga

270 insulin sensitivity as well as with impaired fasting glucose production in Atp7b (-/-) mice.

271 The fasting glucose-raising allele near PDX1, a known key in

272 Thirty type 2 diabetes or fasting glucose-raising alleles were associated with a m

273 Additional adjustment for fasting glucose rendered both coefficients insignificant

274 e red meat diet (P < 0.01) with no change in fasting glucose resulting in a decrease in insulin sensi

275 tein-cholesterol ratio TG/HDL-C, or impaired fasting glucose (serum glucose >/=110 mg/dL) to traditio

276 of plasma PUFAs and concentrations of plasma fasting glucose, serum hsCRP, and plasma lipid mediators

277 bers in Southern Israel who had at least one fasting glucose test during an MO period and at least on

278 s into the regulation of fasting insulin and fasting glucose through the use of gene expression micro

279 esterol, HDL cholesterol, triglycerides, and fasting glucose) to dietary fat.

280 by significantly lower levels of prolactin, fasting glucose, total cholesterol, and triglycerides th

281 te, smoking status, systolic blood pressure, fasting glucose, total cholesterol, antihypertensive med

282 age, blood pressure (treated or untreated), fasting glucose (treated or untreated), body mass index,

283 d physical activity on 1-year change in BMI, fasting glucose, triglycerides, and HDL cholesterol in i

284 Fasting glucose, triglycerides, uric acid, and bilirubin

285 onal 50-g serving of processed meat per day, fasting glucose was 0.021 mmol/L (95% CI: 0.011, 0.030 m

286 The prevalence of abnormal fasting glucose was 40.2%.

287 Mean fasting glucose was 5.29 mmol/L (SD 0.66), mean fasting

288 ancy BMI, each 1-mmol/L increase in maternal fasting glucose was associated with higher SD scores for

289 Fasting glucose was lower after RYGB than after LS/IMM,

290 sulin was measured by chemiluminescence, and fasting glucose was measured with the enzymatic colorime

291 R 3.01, 95% CI 1.60 to 5.65), while impaired fasting glucose was not (OR 1.55, 95% CI 0.70 to 3.44).

292 The adjusted ORs of LGA per 1 SD fasting glucose were 1.22 (95% CI 1.08-1.38) in white Br

293 ults showed that levels of cT1, AST, GGT and fasting glucose were all good predictors of NAS >= 4 and

294 Full montage home-polysomnography and fasting glucose were available on all participants.

295 , systolic and diastolic blood pressure, and fasting glucose were measured.

296 , systolic and diastolic blood pressure, and fasting glucose were measured.

297 Increases in fasting glucose were observed within both groups but wer

298 lipoprotein cholesterol, triglycerides, and fasting glucose were significantly greater after duodena

299 m glycemic changes; and the association with fasting glucose were significantly modified by postpartu

300 rticipants taking KCl had stable or improved fasting glucose, with a mean +/- SD change in fasting gl